Alkermes plc and Taro Pharmaceutical Industries Ltd.: A Detailed Gross Profit Analysis

Pharma Giants' Profit Battle: Alkermes vs. Taro

__timestampAlkermes plcTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014170914000580006000
Thursday, January 1, 2015144942000676585000
Friday, January 1, 2016226424000778966000
Sunday, January 1, 2017335737000671251000
Monday, January 1, 2018492448000463508000
Tuesday, January 1, 2019477729000445724000
Wednesday, January 1, 2020465852000399725000
Friday, January 1, 2021569838000296656000
Saturday, January 1, 2022893687000293122000
Sunday, January 1, 20231410368000268323000
Monday, January 1, 20241312301000304979000
Loading chart...

Cracking the code

A Tale of Two Pharmaceutical Giants: Alkermes plc vs. Taro Pharmaceutical Industries Ltd.

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis delves into the gross profit trends of Alkermes plc and Taro Pharmaceutical Industries Ltd. from 2014 to 2023. Alkermes plc has shown a remarkable growth trajectory, with its gross profit surging by over 700% from 2014 to 2023. In contrast, Taro Pharmaceutical Industries Ltd. experienced a decline of approximately 54% over the same period. Notably, Alkermes plc's gross profit peaked in 2023, while Taro's highest was in 2016. The data reveals a significant shift in market dynamics, highlighting Alkermes plc's strategic advancements. However, the absence of data for Alkermes in 2024 suggests potential challenges or reporting delays. This comparative analysis underscores the importance of strategic planning and market adaptation in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025